These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
66 related articles for article (PubMed ID: 19262224)
21. Atorvastatin affects low density lipoprotein and non-high density lipoprotein cholesterol relations with apolipoprotein B in type 2 diabetes mellitus: modification by triglycerides and cholesteryl ester transfer protein. Kappelle PJ; Zwang L; Huisman MV; Banga JD; Sluiter WJ; Dallinga-Thie GM; Dullaart RP Expert Opin Ther Targets; 2009 Jul; 13(7):743-51. PubMed ID: 19505224 [TBL] [Abstract][Full Text] [Related]
22. Improvement of lipid profile is accompanied by atheroprotective alterations in high-density lipoprotein composition upon tumor necrosis factor blockade: a prospective cohort study in ankylosing spondylitis. van Eijk IC; de Vries MK; Levels JH; Peters MJ; Huizer EE; Dijkmans BA; van der Horst-Bruinsma IE; Hazenberg BP; van de Stadt RJ; Wolbink GJ; Nurmohamed MT Arthritis Rheum; 2009 May; 60(5):1324-30. PubMed ID: 19404933 [TBL] [Abstract][Full Text] [Related]
23. Anacetrapib, a cholesterol ester transfer protein (CETP) inhibitor for the treatment of atherosclerosis. Masson D Curr Opin Investig Drugs; 2009 Sep; 10(9):980-7. PubMed ID: 19705341 [TBL] [Abstract][Full Text] [Related]
24. APOE gene polymorphisms and response to statin therapy. Zintzaras E; Kitsios GD; Triposkiadis F; Lau J; Raman G Pharmacogenomics J; 2009 Aug; 9(4):248-57. PubMed ID: 19529002 [TBL] [Abstract][Full Text] [Related]
26. Beyond LDL cholesterol: the role of elevated triglycerides and low HDL cholesterol in residual CVD risk remaining after statin therapy. Alagona P Am J Manag Care; 2009 Mar; 15(3 Suppl):S65-73. PubMed ID: 19355805 [TBL] [Abstract][Full Text] [Related]
27. A Translational Medicine perspective of the development of torcetrapib: Does the failure of torcetrapib development cast a shadow on future development of lipid modifying agents, HDL elevation strategies or CETP as a viable molecular target for atherosclerosis? A case study of the use of biomarkers and Translational Medicine in atherosclerosis drug discovery and development. Zhao L; Jin W; Rader D; Packard C; Feuerstein G Biochem Pharmacol; 2009 Aug; 78(4):315-25. PubMed ID: 19539799 [TBL] [Abstract][Full Text] [Related]
28. Antihypertensive treatment and its implications on lipoprotein metabolism of patients in care by a hypertension and diabetes program in Brazil. Martins RD; Alves Rde S; Silva GG; Martins N; Vasconcelos S; Assreuy A; Martins A; Goretti Queiroz M Acta Med Port; 2008; 21(6):567-74. PubMed ID: 19331790 [TBL] [Abstract][Full Text] [Related]
29. Association of cholesteryl ester transfer protein -629C > A polymorphism with high-density lipoprotein cholesterol levels in coronary artery disease patients. Tanrikulu S; Ademoglu E; Gurdol F; Mutlu-Turkoglu U; Bilge AK; Nisanci Y Cell Biochem Funct; 2009 Oct; 27(7):452-7. PubMed ID: 19784962 [TBL] [Abstract][Full Text] [Related]
30. Low density lipoprotein apheresis in pediatric patients with homozygous familial hypercholesterolemia. Coker M; Ucar SK; Simsek DG; Darcan S; Bak M; Can S Ther Apher Dial; 2009 Apr; 13(2):121-8. PubMed ID: 19379151 [TBL] [Abstract][Full Text] [Related]
31. Lipoprotein (a) in patients with psoriasis: associations with lipid profiles and disease severity. Pietrzak A; Kadzielewski J; Janowski K; Roliński J; Krasowska D; Chodorowska G; Paszkowski T; Kapeć E; Jastrzebska I; Tabarkiewicz J; Lotti T Int J Dermatol; 2009 Apr; 48(4):379-87. PubMed ID: 19335423 [TBL] [Abstract][Full Text] [Related]
32. Cholesterol and coronary events. The current thinking. Jones PH Postgrad Med; 2003 Apr; 113(4 Suppl):5-14. PubMed ID: 19667618 [TBL] [Abstract][Full Text] [Related]
33. Long-term lipid effects of pioglitazone by baseline anti-hyperglycemia medication therapy and statin use from the PROactive experience (PROactive 14). Spanheimer R; Betteridge DJ; Tan MH; Ferrannini E; Charbonnel B; Am J Cardiol; 2009 Jul; 104(2):234-9. PubMed ID: 19576353 [TBL] [Abstract][Full Text] [Related]
34. Perioperative hypertension: a review of current and emerging therapeutic agents. Marik PE; Varon J J Clin Anesth; 2009 May; 21(3):220-9. PubMed ID: 19464619 [TBL] [Abstract][Full Text] [Related]
35. Low plasma HDL-c, a vascular risk factor in high risk patients independent of LDL-c. Hajer GR; van der Graaf Y; Bots ML; Algra A; Visseren FL; Eur J Clin Invest; 2009 Aug; 39(8):680-8. PubMed ID: 19453647 [TBL] [Abstract][Full Text] [Related]
36. Genetic polymorphisms of tumor necrosis factor-alpha modify the association between dietary polyunsaturated fatty acids and plasma high-density lipoprotein-cholesterol concentrations in a population of young adults. Fontaine-Bisson B; El-Sohemy A J Nutrigenet Nutrigenomics; 2008; 1(5):215-23. PubMed ID: 19776629 [TBL] [Abstract][Full Text] [Related]
37. Usefulness of triglycerides-to-high-density lipoprotein cholesterol ratio for predicting the first coronary event in men. Cordero A; Andrés E; Ordoñez B; León M; Laclaustra M; Grima A; Luengo E; Moreno J; Bes M; Pascual I; Civeira F; Pocoví M; Alegría E; Casasnovas JA; Am J Cardiol; 2009 Nov; 104(10):1393-7. PubMed ID: 19892056 [TBL] [Abstract][Full Text] [Related]
38. [Postprandial changes of blood lipid after ordinary Chinese diet and the influencing factors thereof]. Fu ZF; Liu ML Zhonghua Yi Xue Za Zhi; 2009 Feb; 89(4):260-2. PubMed ID: 19552844 [TBL] [Abstract][Full Text] [Related]
39. Dyslipidemia therapy update: the importance of full lipid profile assessment. Menown IB; Murtagh G; Maher V; Cooney MT; Graham IM; Tomkin G Adv Ther; 2009 Jul; 26(7):711-8. PubMed ID: 19649582 [TBL] [Abstract][Full Text] [Related]
40. Lipid levels in female patients with affective disorders. Sagud M; Mihaljevic-Peles A; Pivac N; Jakovljevic M; Muck-Seler D Psychiatry Res; 2009 Aug; 168(3):218-21. PubMed ID: 19560828 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]